Endzlab Competitors

At LexisNexis Risk Solutions®, we believe in using data for good to solve problems and make a positive impact on people, industry and society. We deliver enhanced value to our customers by leveraging the power of insight through data, advanced analytics and innovative technologies to help them solve problems, make better decisions and improve operations. Our technologies, decision tools and services give our customers a clear advantage in evaluating and predicting risk, enhancing operational efficiency and protecting their consumers. Our businesses span the following sectors: Aviation | Chemicals/Energy | Corporations/Non-Profits | Financial Services | Government | Healthcare | HR | Insurance | Law Enforcement & Public Safety | Tax | Retail/Ecommerce

Qorvo (Nasdaq: QRVO) supplies innovative semiconductor solutions that make a better world possible. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including automotive, consumer, defense & aerospace, industrial & enterprise, infrastructure and mobile. Visit www.qorvo.com to learn how our diverse and innovative team is helping connect, protect and power our planet.

CryoLife’s mission is to partner with clinicians to restore health by delivering innovative technologies. CryoLife is one of the world’s leading medical device companies, providing preserved human tissues for cardiac and vascular surgeries, mechanical heart valves for aortic or mitral valve replacement, surgical adhesives and sealants, vascular grafts, and state-of-the-art technology and surgical training in adult and pediatric cardiovascular surgery. CryoLife is a pioneer and leader in processing, preserving and distributing human tissues, for use in cardiac and vascular surgeries. Founded in 1984, CryoLife was the first biomedical company to specialize in low temperature preservation of human heart valves used for complex cardiac reconstruction, primarily in children born with heart defects. Since the company’s inception, it is estimated that Cryolife has received tissues from over 145,000 donors and CryoLife products and tissues have been implanted in over 1 million patients worldwide. CryoLife is headquartered in Kennesaw, Georgia, with offices in Austin, Texas, Guildford, Surrey, UK, and Hechingen, Germany, as well as sales and marketing centers in Singapore, and representation in over 85 countries worldwide. The firm’s 1000+ employees hail from 11 countries and speak 17 languages. CryoLife’s staff includes numerous full-time physicians and Ph.D.s, with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry. CryoLife is a public company and is traded on the New York Stock Exchange under the symbol CRY.